Key facts
- Notable investors include Johnson & Johnson Innovation - JLABS, Inoh Associates, LabCentral, Power Angels..
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Tenza
- ·The full record, as it builds
Funding rounds
No funding rounds for Tenza are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tenza
Developer of a synthetic biology platform designed to engineer probiotic microbes for in-body production and delivery of therapeutic proteins and peptides. The company's platform offers computationally guided microbial engineering, oral delivery mechanisms, and in vivo synthesis of bioactive compounds, enabling researchers and healthcare developers to improve treatment effectiveness, reduce side effects, and lower production costs.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2018
- Employees
- 10
- Website
- tenza.bio/
- Ownership
- Privately Held (backing)
Tenza doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tenza shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tenza in its N-PORT filings yet. We sweep new filings monthly.